Walid Macaron

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour, Nicholas J. Short, Nitin Jain et al. · The Lancet Haematology · 2022 · 239 citations

Medicine, Hematology, Oncology +12

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML

Nicholas J. Short, Naval Daver, Courtney D. DiNardo et al. · Journal of Clinical Oncology · 2024 · 146 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi et al. · Blood Advances · 2022 · 112 citations · Full text

Medicine, Oncology, Chemotherapy +14

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

Elias Jabbour, Nicholas J. Short, Nitin Jain et al. · The Lancet Haematology · 2022 · 82 citations

Medicine, Hematology, Oncology +12

Ultrasensitive <scp>NGS MRD</scp> assessment in Ph+  <scp>ALL</scp> : Prognostic impact and correlation with <scp>RT‐PCR</scp> for <i>BCR::ABL1</i>

Nicholas J. Short, Elias Jabbour, Walid Macaron et al. · American Journal of Hematology · 2023 · 73 citations · Full text

Medicine, Molecular Biology, Oncology +17